FOOD AND DRUG ADMINISTRATION

First Page		Document Content
Ribbon symbolism Genentech South San Francisco California Trastuzumab Pertuzumab Breast cancer HER2/neu Food and Drug Administration Oncology Drug Advisory Committee Medicine Pharmacology Pharmaceutical sciences		FOOD AND DRUG ADMINISTRATION Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 19,14 KB Share Document on Facebook

	37 \| P a g e Association between age at presentation and pathological features of breast cancer and its effect on survival; a comparative study done in Sri Lanka DocID: 1rdIi - View Document
	Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent DocID: 1rdcC - View Document
	Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with st rd paclitaxel (P) in patients (pts) with 1 - to 3 -line metastatic HER2-negative breast cancer (BC) Monica Mita,1 Carlos Becerra,2 Dona DocID: 1pnOU - View Document
	CURRICULUM VITAE 1. Name: SHAO-CHUN WANG Title and Affiliation: Investigator and Deputy Director China Medical University Hospital DocID: 1pi0O - View Document
	EDITORIAL STAFF From the Editor Debu Tripathy, MD Editor-in-Chief DocID: 1oyvT - View Document